Nasus Pharma Ltd (NSRX)
About Nasus Pharma Ltd
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $1.2B
- Net income
- -$5.9M
- Total assets
- $5.0M
- Market cap
- $34.3M
Source: SEC EDGAR · updated Jun 7, 2026
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $34.3M
- Shares outstanding
- 11.0M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Aug 13, 2025
Nasus Pharma Ltd (NSRX) Stock Price
- Reported a net loss of $5.9M in FY2025.
- Trading 66% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Nasus Pharma Ltd.
Write a review
News about Nasus Pharma Ltd
News & sentiment via Polygon.io
Nasus Pharma Ltd: frequently asked questions
Is Nasus Pharma Ltd an American company?
Nasus Pharma Ltd is a US-based company, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Is Nasus Pharma Ltd publicly traded?
Yes — Nasus Pharma Ltd is a publicly traded company. Its stock trades under the ticker symbol NSRX on the NYSE.
What does Nasus Pharma Ltd do?
Nasus Pharma Ltd is an American Pharmaceuticals company in the Health & Beauty sector.
